Zentalis Pharmaceuticals, Inc. - Common Stock, $0.001 par value per share (ZNTL)

Historical Holders from Q2 2020 to Q4 2025

Type / Class
Equity / Common Stock, $0.001 par value per share
Symbol
ZNTL on Nasdaq
Shares outstanding
68,578,543
Price per share
$1.78
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares as of 30 Sep 2025
52,767,851
Total reported value
$79,681,183
% of total 13F portfolios
0%
Share change
-2,870,813
Value change
-$3,987,959
Avg buy value change
+0%
Avg sell value change
-0%
Number of holders
97
Price from insider filings
$1.20
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Zentalis Pharmaceuticals, Inc. - Common Stock, $0.001 par value per share (ZNTL) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
WALTERS GROUP 20% $20,264,960 13,509,973 Walters William T 31 Dec 2025
Walters William T 9.9% +8.9% $11,209,500 +$874,500 7,050,000 +8.5% Walters William T 29 Jan 2025
5AM Opportunities II (GP), LLC 6.4% $7,257,856 4,838,571 Andrew J. Schwab 18 Dec 2025
BARCLAYS PLC 5.3% $5,800,588 3,841,449 Barclays PLC 30 Sep 2025
VANGUARD GROUP INC 4.6% $5,201,272 3,271,240 The Vanguard Group 31 Dec 2024
BlackRock, Inc. 2.2% $2,081,187 1,613,323 BlackRock, Inc. 30 Jun 2025
MILLENNIUM MANAGEMENT LLC 1.3% -80% $1,272,555 -$4,059,076 902,521 -76% Millennium Management LLC 30 Sep 2025
FMR LLC 0.2% $279,622 175,863 FMR LLC 29 Nov 2024
As of 30 Sep 2025, Zentalis Pharmaceuticals, Inc. - Common Stock, $0.001 par value per share (ZNTL) has 97 institutional shareholders filing 13F forms. They hold 52,767,851 shares. of 68,578,543 outstanding shares (77%) .

Top 25 institutional shareholders own 66% of the company.

Filer Ownership Nb Shares Share Change % Portfolio % Holdings Value
Matrix Capital Management Company, LP 20% 13,959,973 0% 20% $21,079,559
VANGUARD GROUP INC 4.2% 2,904,400 +0.69% 0% $4,385,644
ACADIAN ASSET MANAGEMENT LLC 4.1% 2,845,152 +1.6% 0.01% $4,291,000
RENAISSANCE TECHNOLOGIES LLC 3.4% 2,325,355 +52% 0% $3,511,286
CITADEL ADVISORS LLC 3% 2,077,290 +349% 0% $3,136,708
TANG CAPITAL MANAGEMENT LLC 2.3% 1,550,000 0% 0.09% $2,340,500
BANK OF AMERICA CORP /DE/ 2.3% 1,548,781 +117% 0% $2,338,660
TWO SIGMA ADVISERS, LP 2.1% 1,461,200 +15% 0% $2,206,412
D. E. Shaw & Co., Inc. 2.1% 1,408,803 +18% 0% $2,127,292
MORGAN STANLEY 2.1% 1,407,829 +28% 0% $2,125,823
TWO SIGMA INVESTMENTS, LP 2% 1,363,347 +25% 0% $2,058,654
Decheng Capital LLC 1.9% 1,323,327 0% 0.35% $1,998,224
BlackRock, Inc. 1.8% 1,249,504 -28% 0% $1,886,752
Balyasny Asset Management L.P. 1.7% 1,185,521 +22% 0% $1,790,137
GSA CAPITAL PARTNERS LLP 1.6% 1,077,656 -4.9% 0.14% $1,627,000
PRIMECAP MANAGEMENT CO/CA/ 1.4% 962,620 -6.3% 0% $1,453,556
TYBOURNE CAPITAL MANAGEMENT (HK) LTD 1.4% 961,486 -35% 4.7% $1,451,844
Pfizer Inc 1.4% 953,834 0% 0.33% $1,440,289
MILLENNIUM MANAGEMENT LLC 1.3% 902,521 -74% 0% $1,362,807
JPMORGAN CHASE & CO 1.1% 723,075 +31% 0% $1,091,843
JACOBS LEVY EQUITY MANAGEMENT, INC 1% 700,576 -18% 0% $1,057,870
JANE STREET GROUP, LLC 0.94% 645,623 -2.8% 0% $974,891
GEODE CAPITAL MANAGEMENT, LLC 0.86% 589,222 -4.7% 0% $890,229
Peapod Lane Capital LLC 0.82% 565,371 +1.1% 0.76% $853,879
XTX Topco Ltd 0.8% 548,629 +107% 0.04% $828,430

Institutional Holders of Zentalis Pharmaceuticals, Inc. - Common Stock, $0.001 par value per share (ZNTL) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (% of par) Investors
2025 Q4 130,407 $232,124 -$111,872 178% 1
2025 Q3 52,767,851 $79,681,183 -$3,987,959 151% 97
2025 Q2 55,655,238 $64,573,024 -$4,209,347 116% 115
2025 Q1 58,450,755 $92,928,751 -$20,528,095 159% 131
2024 Q4 64,418,165 $195,184,518 -$24,735,960 303% 141
2024 Q3 70,964,067 $261,155,411 -$21,651,974 368% 133
2024 Q2 76,570,496 $313,184,589 -$53,759,613 409% 142
2024 Q1 85,147,537 $1,341,973,353 +$58,255,702 1,576% 137
2023 Q4 158,655 $2,407,837 +$587,108 1,536.5% 2
2023 Q3 80,022,900 $1,605,262,808 -$51,578,042 2,006% 134
2023 Q2 82,051,216 $2,314,664,922 +$441,938,966 2,821% 129
2023 Q1 67,009,168 $1,152,560,256 +$45,900,649 1,720% 107
2022 Q4 64,325,374 $1,295,448,268 +$105,080,562 2,014% 103
2022 Q3 55,319,392 $1,198,209,830 -$49,423,247 2,166% 108
2022 Q2 58,125,270 $1,633,269,044 +$360,165,764 2,810% 112
2022 Q1 44,290,728 $2,043,860,755 +$46,868,299 4,613.96% 119
2021 Q4 42,840,862 $3,599,617,322 +$96,210,239 8,406% 131
2021 Q3 41,228,145 $2,747,827,141 +$111,592,185 6,664% 112
2021 Q2 39,392,483 $2,095,679,473 +$205,087,800 5,320% 116
2021 Q1 36,317,392 $1,575,761,071 -$55,160,758 4,338.98% 92
2020 Q4 36,895,449 $1,916,351,706 +$310,340,274 5,193.99% 101
2020 Q3 31,635,340 $1,033,195,545 +$169,604,088 3,268.99% 65
2020 Q2 26,858,048 $1,282,608,905 +$1,282,560,925 4,802% 61